Infection

Los Angeles Mayor Karen Bass Honors Dr. Siavash Arani for Healthcare Innovations

Retrieved on: 
Saturday, February 17, 2024

LOS ANGELES, Feb. 16, 2024 /PRNewswire-PRWeb/ -- Dr. Arani, a distinguished physician known for his visionary approach in the field of medicine, especially in the treatment and management of HPV was recognized by Mayor Karen Bass, alongside council members from all 15 districts in a ceremony held at the Los Angeles City Hall.

Key Points: 
  • Presented by Los Angeles 3rd District Councilmember Bob Blumenfied, Dr. Arani is awarded for his outstanding service and dedication to improving patient care in Los Angeles.
  • Dr. Arani stands for us as a shining example of excellence in the field of health care.
  • Dr. Arani then shared his gratitude, "I am deeply honored to receive recognition from Mayor Karen Bass and the city of Los Angeles.
  • Mayor Karen Bass comments on his contributions, "He has developed strategies to treat patients with HPV-related tumors.

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

Retrieved on: 
Saturday, February 17, 2024

The following persons be elected as Directors with immediate effect: (i) Ms Nan Zhang; (ii) Ms Yun (Monica) Zhang; (iii) Mr Lui Chi Keung (Peter); (iv) Mr Jing Xian Li.

Key Points: 
  • The following persons be elected as Directors with immediate effect: (i) Ms Nan Zhang; (ii) Ms Yun (Monica) Zhang; (iii) Mr Lui Chi Keung (Peter); (iv) Mr Jing Xian Li.
  • As of the close of business on the EGM's record date of February 8, 2024, the Company had 188,327,959 ordinary shares issued and outstanding.
  • The results of the vote on each of the resolutions submitted for shareholder approval at the EGM were zero vote in favor and 97,272,542 votes against.
  • Further, Article 88 of the Articles permits a director to attend and be heard on any motion for his removal.

Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 13-14 February 2024

Retrieved on: 
Saturday, February 17, 2024

The Committee adopted by consensus a positive opinion for a variation requiring assessment for Strangvac to implement the outcome of the MAH’s signal management process to add adverse reactions in the product information.

Key Points: 
  • The Committee adopted by consensus a positive opinion for a variation requiring assessment for Strangvac to implement the outcome of the MAH’s signal management process to add adverse reactions in the product information.
  • The respective target species were cattle, pigs and sheep (one product), chickens, and squirrel monkeys (one product each).
  • Concept papers, guidelines
    Quality
    The Committee adopted an annex to the Guideline on quality aspects of pharmaceutical veterinary medicines for administration via drinking water on compatibility studies between veterinary medicinal products and biocidal products (EMA/CVMP/QWP/592906/2022) following close of public consultation.
  • The comments received during the consultation procedure were taken into account for the revision of the annex.

Chronic wasting disease has been detected in British Columbia deer, and we need to act now

Retrieved on: 
Friday, February 16, 2024

Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.

Key Points: 
  • Since 1996, a deadly neurodegenerative disease of cervids (deer, elk, moose, caribou, reindeer) has been spreading across Canada.
  • On Jan. 31, 2024, chronic wasting disease (CWD) was detected for the first time in British Columbia in two deer.

Disease-causing proteins

  • The protein is similar to other normal proteins in the body, except it’s abnormally shaped.
  • The abnormal folding of these disease-causing prion proteins — which are found most abundantly in the brain — leads to brain damage that makes the brain appear like a sponge.
  • Other TSEs include Creutzfeldt-Jakob disease in people, bovine-spongiform encephalopathy (“mad cow disease”) in cows, and scrapie in sheep and goats.
  • This means that early detection and management is critical for reducing the impact of this disease.

British Columbia’s preparations

  • has established a surveillance program to detect CWD as soon as possible.
  • Our research suggests that a robust approach to such a difficult disease will require rapid, collective and collaborative action across sectors.
  • This approach must involve wildlife managers, hunters, local communities, First Nations and researchers to integrate a number of approaches.

Surveillance and management

  • Many CWD management programs rely on removing infected animals from the landscape.
  • While it is mandatory to submit the heads from hunted cervids in select management units in B.C., in most regions, submission is voluntary.
  • Hunters can participate in CWD management and surveillance by removing the head of the animal and submitting it to a local testing station or freezer for CWD testing.
  • The public can also participate in CWD surveillance and management by reporting signs of sick animals and vehicle collisions with cervids.
  • This is why testing cervids that have been killed by vehicles is also a critical component of CWD surveillance and management.

Curbing the spread

  • CWD can spread between animals through contact with bodily fluids.
  • Legal restrictions on carcass transport and the use of urine-based scents in hunting can also reduce the unintentional spread of CWD.
  • Research has shown that community-focused communication and engagement are essential for the success of CWD management efforts.
  • In the days ahead, fostering open dialogue and collaboration will be paramount towards an effective and sustainable effort against CWD.


Kaylee Byers is the Regional Deputy Director of the British Columbia Node of the Canadian Wildlife Health Cooperative and collaborates with the Wildlife Health Program, which leads Chronic Wasting Disease surveillance in British Columbia. Sarah Robinson does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Iovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA Accelerated Approval for Advanced Melanoma

Retrieved on: 
Friday, February 16, 2024

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has approved AMTAGVI™ (lifileucel) suspension for intravenous infusion. AMTAGVI is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response. Iovance is also conducting TILVANCE-301, a Phase 3 trial to confirm clinical benefit.

Key Points: 
  • This indication is approved under an accelerated approval based on overall response rate (ORR) and duration of response.
  • AMTAGVI is the first and the only one-time, individualized T cell therapy to receive FDA approval for a solid tumor cancer.
  • “Given the significant unmet needs in the advanced melanoma community, we are proud to offer a personalized, one-time therapeutic option for these patients.
  • Iovance will host a conference call and live audio webcast today to discuss the FDA approval of AMTAGVI.

FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

Retrieved on: 
Friday, February 16, 2024

"Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).

Key Points: 
  • "Unresectable or metastatic melanoma is an aggressive form of cancer that can be fatal," said Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research (CBER).
  • Melanoma can spread to other parts of the body if not detected and treated early, resulting in metastatic disease.
  • Treatment for unresectable or metastatic melanoma may include immunotherapy using PD-1 inhibitors, which are antibodies targeting certain proteins in the body to help the immune system fight off cancer cells.
  • Those patients whose melanoma has progressed with these therapies have a high unmet medical need.

Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

Retrieved on: 
Friday, February 16, 2024

Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.

Key Points: 
  • Sharps Technology specializes in the development and manufacturing of innovative drug delivery systems.
  • These features protect frontline healthcare workers from life-threatening needle stick injuries and protect the public from the dangers of needle re-use.
  • Their SafeR Retractable Safety Syringe and needles offer a passive safety system with auto-disable reuse prevention features.
  • Additionally, as a Contract Development and Manufacturing Organization (CDMO), they also provide end-to-end services from design to finished products of innovative, safer medical drug delivery solutions.

FDA Approves First Medication to Help Reduce Allergic Reactions to Multiple Foods After Accidental Exposure

Retrieved on: 
Friday, February 16, 2024

Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

Key Points: 
  • Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.
  • "While it will not eliminate food allergies or allow patients to consume food allergens freely, its repeated use will help reduce the health impact if accidental exposure occurs."
  • Current treatment requires strict avoidance of the food(s) the patient is allergic to, and prompt administration of epinephrine to treat anaphylaxis should accidental exposures occur.
  • Xolair is the first FDA-approved medication to reduce allergic reactions to more than one type of food after accidental exposure.

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

Retrieved on: 
Friday, February 16, 2024

People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”).

Key Points: 
  • People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”).
  • Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterized by the rapid onset of symptoms following exposure to certain food allergens.
  • Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies.
  • About 3.4 million children and 13.6 million adults in the U.S. have been diagnosed with IgE-mediated food allergies, based on estimates for 2024.

FDA approves Xolair® (omalizumab) as first and only medicine for children and adults with one or more food allergies

Retrieved on: 
Friday, February 16, 2024

People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as "food allergen avoidance").

Key Points: 
  • People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as "food allergen avoidance").
  • Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterized by the rapid onset of symptoms following exposure to certain food allergens3.
  • Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies.
  • "Given the growing prevalence of food allergies, this news offers hope to the many children and adults who may benefit from a new way to help manage their food allergies."